BLA 020772 · Qol Medcl
Sucraid
Sacrosidase · Oral · Sucrose-specific Enzyme
NovelPriority reviewOrphanLast checked: Nov 20, 2026Latest source record: Aug 2, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1998
Apr 9, 1998
Approved uses
1
Original approval plus efficacy supplements
Registered trials
3
0 Phase 3, 0 recruiting
FAERS reports
181
30 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Dec 29, 2025.
INDICATIONS AND USAGE Sucraid ® (sacrosidase) Oral Solution is indicated for the treatment of sucrase deficiency, which is part of congenital sucrase-isomaltase deficiency (CSID), in adult and pediatric patients 5 months of age and older.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
1 products under this application
- SUCRAID · SACROSIDASE 8,500 IU/ML · SOLUTION, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Sacrosidase" as an intervention, any sponsor and status, largest first.
QOL Medical, LLCIndustry
NCT05480761 · 312 participants · Start Aug 1, 2022 · Primary completion Sep 18, 2024
Drug: Sucraid (sacrosidase) Oral Solution 8500 IU/mL · For: Congenital Sucrase-Isomaltase Deficiency; CSID; Sucrase Isomaltase Deficiency
Sites: Los Angeles, California; Oakland, California; Coral Gables, Florida · 20 sites in all
QOL Medical, LLCIndustry
NCT05703009 · 25 participants · Start Jun 5, 2023 · Primary completion Jan 22, 2024
Drug: Sacrosidase Oral Solution; Placebo · For: Fructan Intolerance
Sites: Boston, Massachusetts
QOL Medical, LLCIndustry
NCT02784067 · 0 participants · Start May 2016 · Primary completion Dec 2017
Drug: Sucraid; Placebo · For: Genetic Sucrase-Isomaltase Deficiency
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- diarrhoea36
- abdominal pain35
- drug ineffective22
- nausea21
- abdominal distension19
- flatulence17
- headache12
- product quality issue12
- dizziness11
- vomiting11
- fatigue9
- insomnia9
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2009 | 1 |
| 2013 | 2 |
| 2014 | 3 |
| 2015 | 2 |
| 2016 | 35 |
| 2017 | 1 |
| 2018 | 6 |
| 2019 | 3 |
| 2020 | 2 |
| 2021 | 2 |
| 2022 | 12 |
| 2023 | 31 |
| 2024 | 37 |
| 2025 | 25 |
| 2026 | 19 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Sucraid (Sacrosidase)
2024 spending
$108M
Beneficiaries
2,168
8,121 claims
Per beneficiary
$49,659
$38.83 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $37,834,003 |
| 2021 | $46,624,899 |
| 2022 | $53,127,582 |
| 2023 | $77,406,308 |
| 2024 | $107,661,425 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Sacrosidase therapy for congenital sucrase-isomaltase deficiency.
Treem WR, McAdams L, Stanford L, et al. · J Pediatr Gastroenterol Nutr 1999 · Clinical Trial, Randomized Controlled Trial
Sponsor: Qol Medcl
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.